UPDATE: Valeant Posts Q3 Net Loss

Loading...
Loading...
Valeant Pharmaceuticals International
VRX
posted a loss in the third quarter. Valeant cut its full-year revenue forecast to a range of $5.7 billion to $5.9 billion, versus its earlier outlook of $5.8 billion to $6.2 billion. Valeant posted a quarterly loss of $973.2 million, or $2.92 per share, versus a year-ago profit of $7.6 million, or $0.02 per share. Excluding special items, its cash earnings climbed to $1.43 per share from $1.15 per share. Its revenue surged 74% to $1.54 billion. However, analysts were expecting earnings of $1.42 per share on revenue of $1.67 billion. Valeant shares fell 3.62% to $105.11 in pre-market trading.
Posted In: EarningsNewsGuidanceloss
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...